Immunotherapy in gastrointestinal cancer: the current scenario and future perspectives

Gastrointestinal cancers (GIC), mostly populated by Colorectal Cancer (CRC), Oesophageal Cancer (OC), Gastric Cancer (GC), Pancreatic Cancer (PC), Hepatocellular cancer (HCC) and biliary tract cancers (BTC) are the most common cause of cancer mortality worldwide with significant associated morbidity. If managed early, radical approaches can lead to better outcomes, contrasted with less than 15% in advanced stage disease[1]. Unfortunately, many patients are diagnosed late –for example up to 79% of those with PC are diagnosed at stage III or above in the UK[2].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research